NBL-028 for advanced solid tumors with CLDN6
Part of Cancer clinical trials.
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your tumor has a specific protein marker called Claudin-6 (CLDN6)
- You have tried standard treatments and they did not work or you could not tolerate them
- You have at least one tumor that can be measured on a scan
- You are able to get around and take care of yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This trial tests a new drug called TJ037130 for people with advanced solid tumors that have a specific protein called Claudin 6 (CLDN6) on their cells. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.